Profile data is unavailable for this security.
About the company
Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.
- Revenue in USD (TTM)160.40m
- Net income in USD-62.64m
- Incorporated2019
- Employees180.00
- LocationArcturus Therapeutics Holdings Inc10628 Science Center Dr Ste 250SAN DIEGO 92121-1132United StatesUSA
- Phone+1 (858) 900-2660
- Fax+1 (302) 636-5454
- Websitehttps://arcturusrx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Altimmune Inc | 409.00k | -101.35m | 522.37m | 59.00 | -- | 3.42 | -- | 1,277.19 | -1.62 | -1.62 | 0.0064 | 2.15 | 0.0023 | -- | 1.46 | 6,932.20 | -56.83 | -39.62 | -61.41 | -42.58 | -- | -- | -24,778.97 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
Prime Medicine Inc | 591.00k | -217.44m | 526.94m | 234.00 | -- | 2.68 | -- | 891.60 | -2.16 | -2.16 | 0.0058 | 1.64 | 0.0022 | -- | -- | 2,525.64 | -80.45 | -- | -88.55 | -- | -- | -- | -36,791.71 | -- | -- | -- | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
Chromadex Corp | 91.67m | 1.49m | 535.45m | 106.00 | 370.31 | 15.51 | 230.20 | 5.84 | 0.0189 | 0.0189 | 1.21 | 0.4521 | 1.67 | 3.05 | 23.51 | 864,792.40 | 2.70 | -42.11 | 4.08 | -65.14 | 61.45 | 59.68 | 1.62 | -30.64 | 2.35 | -- | 0.0004 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
Kezar Life Sciences Inc | 7.00m | -98.57m | 542.84m | 58.00 | -- | 0.3599 | -- | 77.55 | -13.55 | -13.55 | 0.962 | 20.67 | 0.0316 | -- | -- | 120,689.70 | -44.47 | -32.54 | -47.84 | -34.09 | -- | -- | -1,408.11 | -4,308.11 | -- | -- | 0.0634 | -- | -- | -- | -49.28 | -- | 10.08 | -- |
Verve Therapeutics Inc | 24.40m | -197.03m | 543.54m | 255.00 | -- | 1.07 | -- | 22.28 | -2.46 | -2.46 | 0.3033 | 6.01 | 0.0382 | -- | 8.45 | 95,670.59 | -30.87 | -- | -32.86 | -- | -- | -- | -807.62 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
OmniAB Inc | 21.71m | -62.38m | 543.55m | 106.00 | -- | 1.85 | -- | 25.03 | -0.6204 | -0.6204 | 0.2159 | 2.49 | 0.0585 | -- | 2.80 | 204,849.10 | -16.80 | -- | -17.72 | -- | -- | -- | -287.29 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
Kalvista Pharmaceuticals Inc | 0.00 | -141.77m | 544.32m | 150.00 | -- | 2.76 | -- | -- | -3.54 | -3.54 | 0.00 | 4.01 | 0.00 | -- | -- | 0.00 | -78.65 | -40.63 | -87.52 | -43.67 | -- | -- | -- | -2,972.81 | -- | -- | 0.00 | -- | -- | -- | -36.31 | -- | -16.34 | -- |
MeiraGTx Holdings PLC | 8.12m | -93.14m | 548.01m | 387.00 | -- | 5.74 | -- | 67.47 | -1.49 | -1.49 | 0.1298 | 1.24 | 0.0282 | -- | 0.4733 | 19,384.25 | -32.29 | -26.40 | -40.66 | -32.66 | -- | -- | -1,146.81 | -420.70 | -- | -22.76 | 0.4759 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
Q32 Bio Inc | 0.00 | -49.66m | 548.25m | 42.00 | -- | 29.86 | -- | -- | -7.44 | -7.44 | 0.00 | 1.51 | 0.00 | -- | -- | 0.00 | -27.86 | -34.98 | -33.25 | -37.92 | -- | -- | -- | -971.76 | -- | -- | 0.4079 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
Arcturus Therapeutics Holdings Inc | 160.40m | -62.64m | 550.85m | 180.00 | -- | 2.11 | -- | 3.43 | -2.33 | -2.33 | 5.95 | 9.67 | 0.3873 | -- | 4.69 | 891,105.60 | -15.13 | -19.66 | -18.67 | -24.90 | -- | -- | -39.05 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
Aura Biosciences Inc | 0.00 | -80.69m | 552.61m | 88.00 | -- | 2.89 | -- | -- | -1.79 | -1.79 | 0.00 | 3.86 | 0.00 | -- | -- | 0.00 | -39.26 | -- | -41.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
Sangamo Therapeutics Inc | 12.28m | -249.68m | 562.20m | 405.00 | -- | 23.73 | -- | 45.79 | -1.38 | -1.38 | 0.0664 | 0.1138 | 0.0587 | -- | 7.45 | 30,313.58 | -119.44 | -26.09 | -153.51 | -31.04 | -- | -- | -2,033.68 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
Regenxbio Inc | 84.33m | -238.81m | 572.74m | 344.00 | -- | 1.90 | -- | 6.79 | -5.03 | -5.03 | 1.76 | 6.09 | 0.1463 | -- | 3.27 | 245,136.60 | -41.43 | -16.75 | -51.75 | -19.08 | 54.36 | 78.27 | -283.19 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
Celcuity Inc | 0.00 | -82.59m | 581.37m | 55.00 | -- | 3.29 | -- | -- | -2.74 | -2.74 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -37.03 | -37.32 | -39.38 | -39.16 | -- | -- | -- | -- | -- | -- | 0.3525 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
Holder | Shares | % Held |
---|---|---|
Federated Global Investment Management Corp.as of 30 Jun 2024 | 4.69m | 17.36% |
Nikko Asset Management Americas, Inc.as of 30 Sep 2024 | 2.32m | 8.56% |
ARK Investment Management LLCas of 30 Sep 2024 | 2.10m | 7.77% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 2.02m | 7.49% |
SSgA Funds Management, Inc.as of 30 Jun 2024 | 1.52m | 5.64% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 1.32m | 4.90% |
Morgan Stanley & Co. LLCas of 30 Jun 2024 | 768.29k | 2.84% |
Woodline Partners LPas of 30 Jun 2024 | 754.02k | 2.79% |
Dimensional Fund Advisors LPas of 30 Sep 2024 | 741.36k | 2.74% |
Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 555.50k | 2.05% |